AI evidence summary · MVP
Saw Palmetto for Benign Prostatic Hyperplasia
AI preliminary evidence assessment
CC 級｜AI 整體初步評級
This preliminary assessment is currently available in Traditional Chinese.
Exact question對已診斷良性攝護腺肥大或其下泌尿道症狀的成人，口服單方鋸棕櫚相較安慰劑或相同共照，是否改善尿路症狀與生活品質，並有哪些不良反應？
已驗證的10份直接研究結果方向不一致：STEP與CAMUS的鋸棕櫚單方安慰劑比較未見症狀或生活品質優勢，中國19中心試驗呈正向結果；相同α阻斷劑共照研究亦有零結果、儲尿分量表或其他正向訊號。不同製劑、共照與設計不能合成「所有鋸棕櫚都有效」的結論。本次保守計數使用7個有來源支持的研究單位，另3篇獨立性未明仍保留結果與限制；最終字母等級由既有scorer加權與證據層級規則產生，不是正式GRADE。
Additional assessment reasons await presentation; see the research results below.
Limitations affecting this assessment
- 封存資料僅有PubMed摘要，未完成全文、附錄及原始統計資料查核；配方標準化、盲法、隨機化、遺失追蹤、停藥與資助資訊多不完整。
- 18份來源中，6份屬合格但來源受限：PMID11744467與16175413未能由摘要確認BPH診斷或歸因；PMID12497097未交代對照照護；PMID20098586主要為組內變化；PMID28991765的症狀改善亦主要是組內結果；PMID32620155未提供可抽取的傳統鋸棕櫚油對安慰劑症狀比較。這些均未當作獨立直接療效單位。
- 三份保留療效結果的報告未獨立計數：PMID10732392僅為一人交替暴露病例；PMID12887481的招募地點及跨報告身分未確認；PMID2418902的Permixon雙盲試驗身分資料不足。保守不計數不代表已證明參與者沒有重疊。
- 直接結果異質性明顯：萃取方式包含標準化、脂固醇、己烷、酒精及油劑，劑量與療程不同；部分為單方對安慰劑，部分是在坦索羅辛、賽洛多辛或阿夫唑嗪背景上加藥，不能視為同一介入效果。
- PMID29123161為單一義大利診所、前瞻收集後回溯分組的觀察比較，易受選擇與混雜影響；PMID41098072雖稱隨機多中心實務研究，但摘要僅提供2023年倫理核准日期而非招募期間，且主要呈現時間交互作用而非一致的治療主效應。
- 多項正向研究樣本較小、報告選擇性或設計限制較大；相較之下，STEP與CAMUS是不同時期的美國大型試驗，且NCT00097136只是CAMUS別名，不能重複計數。
- 安全性資料主要屬短期且事件稀少；α阻斷劑共照研究中的不良反應難以單獨歸因於鋸棕櫚。資助與利益衝突資訊在封存摘要中多不明。
- 另有72筆配方、族群或書目資訊未解的紀錄，以及兩份配方不明的背景報告；它們既不能支持療效，也不能當作反證。系統性回顧、指引與其他背景資料不增加獨立受試者。
- PMID6085231的PA109成分未能確認，僅保留為成分未知的來源涵蓋資訊，不列為直接療效結果或獨立研究計數。
- 原有13個必要L4/L5/L10快取沿既有provenance重用，未宣稱本輪重新查證；L1缺失沿原中性政策，72筆未解來源保留範圍限制。
- 整體初評C來自既有加權與證據層級規則，表示本專案的初步支持級別，不代表所有鋸棕櫚製劑有效或療效強。獨立L11交叉評讀為D，著重STEP、CAMUS與OCOS零結果；最終C保留L2結果不一致、其他層及原缺失中性政策的影響，不能把層間差異掩蓋為一致結論。
- 本次整體初評採保守計數：7個有來源支持的研究單位、另3篇獨立性未明；全部10份結果保留。這不證明所有參與者互不重複，不把合併用藥結果當單方效果。
Research results
Findings are currently provided in Traditional Chinese; source excerpts retain their original language.
Main result 1
單一患者基線AUASI為20；未盲SPE後為7、其後雙盲安慰劑為14、最後單盲SPE為11，兩個SPE期的分數均低於安慰劑期，但這是N=1交替個案。
Applicability assessment: 症狀性BPH單一患者有鋸棕櫚與安慰劑交替期；僅能提供個案層級資料。
- Population
- 一名67歲症狀性BPH男性
- Intervention
- 標準化鋸棕櫚萃取物160 mg，每日兩次
- Comparator
- 交替期的安慰劑
- Outcome
- AUASI尿路症狀分數
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- 160 mg standardized extract twice daily
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 2
52週329名隨機患者中，52週總IPSS變化、排尿與儲尿分項、反應者比例及兩種QoL量表均無顯著組間差異；未顯示加用Serenoa repens的額外效益。
Applicability assessment: 症狀性BPH患者接受相同坦索羅辛治療，可比較加用Serenoa repens的效果。
- Population
- 有BPH症狀的患者
- Intervention
- 坦索羅辛加Serenoa repens 160 mg每日兩次
- Comparator
- 坦索羅辛加安慰劑
- Outcome
- IPSS症狀分數及生活品質
- Follow-up
- 52週
- Formulation
- Not established
- Dose
- Serenoa repens 160 mg twice daily, added to tamsulosin 0.4 mg once daily
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 3
12週12週內IPSS在鋸棕櫚與安慰劑間無顯著差異；兩組症狀均改善，不能把治療組內改善解讀為介入效果。
Applicability assessment: BPH症狀男性隨機接受Serenoa repens萃取物或安慰劑。
- Population
- 有BPH症狀的男性
- Intervention
- Serenoa repens萃取物320 mg
- Comparator
- 石蠟油安慰劑
- Outcome
- IPSS症狀分數
- Follow-up
- 12週
- Formulation
- Not established
- Dose
- 320 mg S. repens extract daily
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 4
一年一年時AUASI變化的平均組間差為0.04分（95% CI -0.93至1.01），生活品質亦無顯著組間差異。
Applicability assessment: 中重度症狀性BPH男性隨機接受鋸棕櫚萃取物或安慰劑。
- Population
- 49歲以上、具有中重度BPH症狀的男性
- Intervention
- 鋸棕櫚萃取物160 mg，每日兩次
- Comparator
- 安慰劑
- Outcome
- AUASI症狀分數及生活品質
- Follow-up
- 一年
- Formulation
- Not established
- Dose
- Saw palmetto extract 160 mg twice daily
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 5
72週72週AUASI下降幅度安慰劑反而較大；組間變化差0.79分偏向安慰劑，且所有次要結果均未顯示鋸棕櫚優於安慰劑。
Applicability assessment: BPH相關下泌尿道症狀男性接受鋸棕櫚萃取物或安慰劑。
- Population
- 45歲以上、有BPH相關下泌尿道症狀的男性
- Intervention
- 鋸棕櫚萃取物，逐步增加至每日三份320 mg
- Comparator
- 安慰劑
- Outcome
- AUASI症狀分數
- Follow-up
- 72週
- Formulation
- Not established
- Dose
- 320 mg/day, increased to 640 mg/day at 24 weeks and 960 mg/day at 48 weeks
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 6
兩組尿流與主觀症狀均有改善，但治療結果無顯著組間差異；組內改善不構成Permixon優於安慰劑的證據。
Applicability assessment: 良性攝護腺肥大患者接受Permixon與安慰劑比較；摘要未提供療程。
- Population
- 良性攝護腺肥大患者
- Intervention
- Permixon 160 mg，每日兩次
- Comparator
- 安慰劑
- Outcome
- 主觀症狀評估及尿流率
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Permixon 160 mg twice daily
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 7
12個月12個月總IPSS與LUTS相關QoL無顯著組間差異，但儲尿症狀分項較tamsulosin單用改善更多；屬分項正向而整體症狀/QoL陰性的混合結果。
Applicability assessment: 症狀性BPH男性接受相同坦索羅辛治療，並比較有無加用Serenoa repens。
- Population
- 有症狀性BPH的男性
- Intervention
- 坦索羅辛0.2 mg／日加Serenoa repens 320 mg／日
- Comparator
- 單用坦索羅辛0.2 mg／日
- Outcome
- 總IPSS、儲尿症狀及LUTS相關生活品質
- Follow-up
- 12個月
- Formulation
- Not established
- Dose
- Serenoa repens 320 mg/day added to tamsulosin 0.2 mg/day
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 8
平均13.5個月時，加用Serenoa組IPSS較低，達到超過3分或超過25%改善的比例亦較高；但並非摘要所證實的隨機分派結果。
Applicability assessment: LUTS患者在silodosin治療下比較有無加用Serenoa repens；摘要未稱隨機分派。
- Population
- 有下泌尿道症狀的患者
- Intervention
- silodosin加六烷脂質固醇Serenoa repens萃取物
- Comparator
- 單用silodosin
- Outcome
- IPSS症狀分數及臨床重要改善
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Hexanic lipidosterolic Serenoa repens extract added to silodosin; dose not stated in the abstract
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 9
24週24週鋸棕櫚組相較安慰劑在IPSS、儲尿與排尿症狀及QoL均有統計顯著改善，但摘要未提供各端點的效應量。
Applicability assessment: LUTS／BPH患者隨機接受Serenoa repens萃取物或安慰劑。
- Population
- 中國的LUTS／BPH患者
- Intervention
- Serenoa repens萃取物320 mg
- Comparator
- 安慰劑
- Outcome
- IPSS、儲尿與排尿症狀及生活品質
- Follow-up
- 24週
- Formulation
- Not established
- Dose
- Serenoa repens extract 320 mg daily
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceMain result 10
12個月兩組IPSS皆改善，但加用HESr組跨時間點IPSS較低，時間×治療交互作用p=0.007；摘要亦稱自第3個月起LUTS效益較大。
Applicability assessment: BPH相關LUTS男性在相同alfuzosin治療下，比較有無加用Serenoa repens萃取物。
- Population
- BPH所致中重度下泌尿道症狀男性
- Intervention
- alfuzosin 10 mg加標準化Serenoa repens萃取物320 mg／日
- Comparator
- 單用alfuzosin 10 mg／日
- Outcome
- 總IPSS
- Follow-up
- 12個月
- Formulation
- Not established
- Dose
- Standardized Serenoa repens extract 320 mg/day added to alfuzosin 10 mg/day
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 11
6個月摘要提供症狀分數、生活品質及尿流率的評估資料。
Applicability assessment: 研究納入有下泌尿道症狀的男性，但摘要未明確指出BPH診斷。
- Population
- 45歲以上且IPSS至少8分的男性
- Intervention
- 鋸棕櫚
- Comparator
- 安慰劑
- Outcome
- IPSS、生活品質及尿流率
- Follow-up
- 6個月
- Formulation
- Not established
- Dose
- Not established
Source excerpt: Patients were evaluated using the International Prostate Symptom Score, a sexual function questionnaire, and by measurement of the urinary flow rate.View source
Safety finding 12
52週摘要僅將安全性列為無顯著組間差異，未提供事件數、分母、事件類型或因不良事件停藥數。
Applicability assessment: 相同坦索羅辛共照下比較加用Serenoa repens與安慰劑的安全性。
- Population
- 有BPH症狀的患者
- Intervention
- 坦索羅辛加Serenoa repens 160 mg每日兩次
- Comparator
- 坦索羅辛加安慰劑
- Outcome
- 安全性
- Follow-up
- 52週
- Formulation
- Not established
- Dose
- Serenoa repens 160 mg twice daily, added to tamsulosin 0.4 mg once daily
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 13
9週摘要提供治療前後的IPSS、生活品質及尿動力學資料。
Applicability assessment: 研究有BPH患者及對照組，但摘要未說明對照組接受何種處置。
- Population
- 輕至中度BPH所致下泌尿道症狀患者
- Intervention
- Permixon 160 mg每日兩次
- Comparator
- 處置未明的對照組
- Outcome
- IPSS、生活品質及尿動力學指標
- Follow-up
- 9週
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 14
24個月摘要提供IPSS、生活品質及臨床進展的資料。
Applicability assessment: 研究對象有輕度膀胱出口阻塞症狀，但摘要未確認BPH診斷。
- Population
- 有輕度膀胱出口阻塞症狀的男性
- Intervention
- Serona repens植物療法
- Comparator
- 觀察等待
- Outcome
- IPSS、生活品質及臨床進展
- Follow-up
- 24個月
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSafety finding 15
一年摘要僅稱兩組副作用發生率相近，未提供確切事件數、分母、種類或停藥數。
Applicability assessment: BPH患者接受鋸棕櫚萃取物或安慰劑，摘要比較兩組副作用。
- Population
- 49歲以上、具有中重度BPH症狀的男性
- Intervention
- 鋸棕櫚萃取物160 mg，每日兩次
- Comparator
- 安慰劑
- Outcome
- 副作用發生率
- Follow-up
- 一年
- Formulation
- Not established
- Dose
- Saw palmetto extract 160 mg twice daily
Source excerpt: The incidence of side effects was similar in the two groups.View source
Additional finding 16
12個月摘要涵蓋鋸棕櫚油單方組、安慰劑組及症狀與生活品質測量。
Applicability assessment: 研究有BPH患者、鋸棕櫚油單方組及安慰劑組，但摘要主要報告組內變化。
- Population
- 有BPH的患者
- Intervention
- 鋸棕櫚油320 mg／日
- Comparator
- 甘藷澱粉安慰劑
- Outcome
- 國際攝護腺症狀分數及生活品質
- Follow-up
- 12個月
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSafety finding 17
72週摘要僅質性表示未辨識出明確可歸因的不良作用，沒有事件數、分母、撤退或停藥細節。
Applicability assessment: 鋸棕櫚萃取物與安慰劑試驗的摘要報告可歸因不良作用。
- Population
- 45歲以上、有BPH相關下泌尿道症狀的男性
- Intervention
- 鋸棕櫚萃取物，逐步增加至每日三份320 mg
- Comparator
- 安慰劑
- Outcome
- 可歸因的不良作用
- Follow-up
- 72週
- Formulation
- Not established
- Dose
- 320 mg/day, increased to 640 mg/day at 24 weeks and 960 mg/day at 48 weeks
Source excerpt: No clearly attributable adverse effects were identified.View source
Safety finding 18
12個月藥物相關不良反應為tamsulosin組8人（16.9%），tamsulosin加Serenoa組10人（20%）；摘要列出事件類型，但未逐類計數或說明因事件停藥。
Applicability assessment: 相同坦索羅辛共照下，摘要比較加用Serenoa repens與未加用者的藥物相關不良反應。
- Population
- 有症狀性BPH的男性
- Intervention
- 坦索羅辛0.2 mg／日加Serenoa repens 320 mg／日
- Comparator
- 單用坦索羅辛0.2 mg／日
- Outcome
- 藥物相關不良反應
- Follow-up
- 12個月
- Formulation
- Not established
- Dose
- Serenoa repens 320 mg/day added to tamsulosin 0.2 mg/day
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 19
12個月摘要提供IPSS、尿流率及攝護腺體積資料。
Applicability assessment: 症狀性BPH男性接受Serenoa repens萃取物或未治療觀察；摘要未稱隨機分派。
- Population
- 40至79歲症狀性BPH男性
- Intervention
- Serenoa repens酒精萃取物
- Comparator
- 未治療、僅觀察
- Outcome
- IPSS、尿流率及攝護腺體積
- Follow-up
- 12個月
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceSafety finding 20
24週至少一項不良事件：安慰劑169人中2人（1.18%）；Serenoa組159人中3人（原文作1.89，應保留原文呈現）。摘要未說明事件類型、嚴重度或停藥。
Applicability assessment: LUTS／BPH患者接受Serenoa repens萃取物或安慰劑，摘要報告不良事件。
- Population
- 中國的LUTS／BPH患者
- Intervention
- Serenoa repens萃取物320 mg
- Comparator
- 安慰劑
- Outcome
- 至少一項不良事件
- Follow-up
- 24週
- Formulation
- Not established
- Dose
- Serenoa repens extract 320 mg daily
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 21
12週摘要說明三組比較，並以IPSS評估BPH嚴重度。
Applicability assessment: 症狀性BPH患者接受富含β-谷固醇的鋸棕櫚油、一般鋸棕櫚油或安慰劑。
- Population
- 40至65歲症狀性BPH受試者
- Intervention
- 富含β-谷固醇的鋸棕櫚油500 mg
- Comparator
- 安慰劑；另有一般鋸棕櫚油組
- Outcome
- 國際攝護腺症狀評分（IPSS）
- Follow-up
- 12週
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 22
12週摘要提供IPSS及最大尿流率的比較資料。
Applicability assessment: 研究對象有BPH相關下泌尿道症狀，但介入產品Prostataplex的成分未在摘要中說明。
- Population
- 49至75歲、有BPH相關下泌尿道症狀的中國男性
- Intervention
- Prostataplex軟膠囊每日兩粒
- Comparator
- 安慰劑軟膠囊
- Outcome
- IPSS及最大尿流率
- Follow-up
- 12週
- Formulation
- Not established
- Dose
- Not established
No additional short excerpt is shown for this finding. See the linked source to check the result.
View sourceAdditional finding 23
一個月摘要提供夜間頻尿、尿量、排尿後殘餘尿及主觀排尿症狀的評估資料。
Applicability assessment: 研究比較試驗製劑與安慰劑治療有症狀的攝護腺腺瘤患者，但摘要未提供製劑成分資訊。
- Population
- 有症狀且可接受藥物治療的攝護腺腺瘤患者
- Intervention
- 成分未明的試驗製劑
- Comparator
- 安慰劑
- Outcome
- 夜間頻尿、尿量、排尿後殘餘尿及排尿困難
- Follow-up
- 一個月
- Formulation
- Not established
- Dose
- Not established
Source excerpt: whose effectiveness was assessed after one month on the basis of objective criteria (nocturnal pollakiuria, urinary output, postmictional residue) and subjective criteria (dysuria, patients' opinions)View source
Sources consulted
- Benign prostatic hyperplasia treated with saw palmetto: a literature search and an experimental case study. Abstract only · 2026-09-28T04:45:08.364087Z
- Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Context source; not counted as an included human-result report Abstract only · 2026-09-28T04:45:08.364087Z
- [Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial]. Abstract only · 2026-09-28T04:45:08.364087Z
- Early urodynamic effects of the lipido-sterolic extract of Serenoa repens (Permixon(R)) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Context source; not counted as an included human-result report Abstract only · 2026-09-28T04:45:08.364087Z
- Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. Abstract only · 2026-09-28T04:45:08.364087Z
- Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting. Context source; not counted as an included human-result report Abstract only · 2026-09-28T04:45:08.364087Z
- Saw palmetto for benign prostatic hyperplasia. Abstract only · 2026-09-28T04:45:08.364087Z
- Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. Context source; not counted as an included human-result report Abstract only · 2026-09-28T04:45:08.364087Z
- Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Context source; not counted as an included human-result report Abstract only · 2026-09-28T04:45:08.364087Z
- Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. Abstract only · 2026-09-28T04:45:08.364087Z
- The value of permixon in benign prostatic hypertrophy. Abstract only · 2026-09-28T04:45:08.364087Z
- Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Abstract only · 2026-09-28T04:45:08.364087Z
- Effects of Serenoa repens Alcohol Extract on Benign Prostate Hyperplasia. Context source; not counted as an included human-result report Abstract only · 2026-09-28T04:45:08.364087Z
- Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone. Abstract only · 2026-09-28T04:45:08.364087Z
- Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Abstract only · 2026-09-28T04:45:08.364087Z
- A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. Context source; not counted as an included human-result report Abstract only · 2026-09-28T04:45:08.364087Z
- Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study. Abstract only · 2026-09-28T04:45:08.364087Z
- [Medical treatment of prostatic adenoma. Controlled trial: PA 109 vs placebo in 110 patients]. Context source; not counted as an included human-result report Abstract only · 2026-09-28T04:45:08.364087Z
Reading and assessment notes
This is an AI preliminary assessment, not expert review or formal GRADE. Read the method and common limitations.
Absence of reported harms does not establish safety. This summary does not provide individual treatment or dosing advice.
Data and assessment record
Search coverage for this case
對已診斷良性攝護腺肥大或其下泌尿道症狀的成人，口服單方鋸棕櫚相較安慰劑或相同共照，是否改善尿路症狀與生活品質，並有哪些不良反應？
Searched：2026-09-28T04:45:08.364087Z · Databases：PubMed
458 records identified; 458 screened; 10 reports included, representing at least 7 study populations. Some relationships remain unresolved.
Some included reports were assessed without full text.
- 部分候選文獻未取得全文，完整偏倚風險與次要結果評讀受限。
- 系統檢索限於 PubMed；未涵蓋所有資料庫與完整引文追查。
Processing record
Evidence summary available
Sources through：2026-09-28 · Generated：2026-10-05T06:36:48.542227+00:00
Retrieved 458 records · Screened 458 · Included 10 reports · Omitted 448
Run：bph-rated-final-20261005
codex_cli / gpt-5.6-sol / problem-search-source-bound-l2+l11-v1
{
"included": 10,
"limits_hit": [
"fulltext_unavailable",
"limited_citation_tracing"
],
"omitted": 448,
"retrieved": 458,
"screened": 458
} sha256:c450cec9971c1a10ca5781651629fda5dc6035d3e7bcbc91a9914b3ca266ddca